李晋 贺敬敬 易蕊 王恒恩 吴佳君.左旋多巴/ 卡比多巴联合恩他卡朋治疗帕金森病的临床研究[J].,2016,16(3):504-506 |
左旋多巴/ 卡比多巴联合恩他卡朋治疗帕金森病的临床研究 |
A Clinical Study of Levodopa/carbidopa Combined with Entacapone inParkinson's Disease |
|
DOI: |
中文关键词: 恩他卡朋 左旋多巴 卡比多巴 帕金森病 临床研究 |
英文关键词: Entacapone Levodopa Carbidopa Parkinson's disease Clinical analysis |
基金项目: |
|
摘要点击次数: 773 |
全文下载次数: 0 |
中文摘要: |
目的:观察左旋多巴/ 卡比多巴联合恩他卡朋(levodopa/carbidopa combined with entacapone, LC+E)治疗帕金森病(Parkinson's
disease, PD)的临床效果。方法:选择我院2013 年1 月~2014 年6 月收治的112 例PD 患者,随机分为两组。其中对照组52
例采用左旋多巴/ 卡比多巴(LC)治疗,观察组60 例采用左旋多巴/卡比多巴联合恩他卡朋(LC+E)治疗。观察并比较两组治疗前
后帕金森病评分量表(Unified Parkinson's Disease Rating Scale, UPDRS)的评分变化情况。结果:与治疗前比较,治疗后两组UPDRS-
II 日常生活能力评分,UPDRS-III 运动能力评分显著下降,而UPDRS-VI SCHWAB&ENGLAND 日常活动能力评分显著上
升,差异有统计学意义(P<0.05);观察组各项变化情况比对照组明显,差异有统计学意义(P<0.05)。两组UPDRS-I精神、行为、情
绪和Hoehn 与Yahr 分级均无显著改善,差异无统计学意义(P>0.05)。结论:左旋多巴/卡比多巴联合恩他卡朋可明显缓解PD症
状,疗效优于左旋多巴/ 卡比多巴治疗,且安全性高,值得临床推广。 |
英文摘要: |
Objective:To investigate the clinical effect of levodopa/carbidopa combined with entacapone (LC+E) in the treatment
of Parkinson's disease (PD).Methods:112 patients with PD who were treated in our hospital from January 2013 to June 2014 were selected
and randomly divided into two groups. The patients in the control group (n=52) were treated with levodopa/carbidopa (LC), while
the patients in the observation group (n=60) were treated with levodopa/carbidopa combined with entacapone (LC+E). Then the changes
ofUnified Parkinson'sDisease RatingScale (UPDRS) inthe twogroups were observedand comparedbefore and after the treatment.Results:After treatment, UPDRS-II of ability of daily life, UPDRS-III of motion examination and UPDRS-IV of complications in the two groups
significantly decreased, and UPDRS-VI of SCHWAB&ENGLAND scale of the ability of daily life increased (P<0.05); The changes of
the observation group were significantly than those of the control group, and the differences were statistically significant (P<0.05). There
was no significant difference about the UPDRS-I of mental, behavioral and emotional and UPDRS-V of the modify Hoehn and Yahr
classification between the two groups (P>0.05).Conclusion:LC+E can significantly relieve the symptoms of PD, which is much better
than that in LC. And, it has a higher safety. It is worth the clinical promotion. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |